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Breast cancer patients with metastatic disease have a higher incidence of deaths from
breast cancer than patients with early-stage cancers. Recent findings suggest that there
are differences in immune cell function between metastatic and non-metastatic cases,
even years before diagnosis. We have analyzed whole blood gene expression by Illumina
bead chips in blood samples taken using the PAXgene blood collection system up to two
years before diagnosis. The final study sample included 197 breast cancer cases and 197
age-matched controls. We defined a causal directed acyclic graph to guide a Bayesian
data analysis to estimate the risk of metastasis associated with the expression of all genes
and with relevant sets of genes. We ranked genes and gene sets according to the sign
probability for excess risk. Among the screening detected cancers, 82% were without
metastasis, compared to 53% of between-screening detected cancers. Among the
highest ranking genes and gene sets associated with metastasis risk, we identified
plasmacytiod dentritic cell function, the SLC22 family of transporters, and glutamine
metabolism as potential links between the immune system and metastasis. We conclude
that there may be potentially wide-reaching differences in blood gene expression profiles
between metastatic and non-metastatic breast cancer cases up to two years before
diagnosis, which warrants future study.
Keywords: breast cancer, metastasis, transcriptomics, blood, immune system, Bayesian data analysis,
causal diagramsINTRODUCTION
In recent decades, survival of breast cancer has increased substantially (1). However, among breast
cancer patients, the proportion of deaths due to breast cancer increases with advanced tumor stage,
particularly for metastatic cancer (2). Improving our understanding of metastatic disease may lead
to better diagnosis and increased survival.
The host immune response plays an important role in modulating the progression of cancer,
including the progression of metastasis (3). The fate of a disseminated cancer cell depends on itsOctober 2020 | Volume 10 | Article 5754611
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transit through the circulatory system. Its fate also depends on
escaping from clearance by the immune system (4). A study on
node-positive (metastatic) and node-negative (non-metastatic)
breast cancer patients showed different mRNA gene expression
patterns, both in tumors and lymph nodes, but also in the
peripheral blood (5). In the blood cells of non-metastatic
patients, gene expression patterns related to lymphocyte
activation and B-cells were up-regulated, indicating a systemic
down-regulation of immune function in patients with
metastasis (5).
The diagnostic potential of blood gene expression profiles for
breast cancer has been investigated in blood samples taken at the
time of diagnosis (6). But so far only diagnostic gene expression
tests based on tumor tissue have reached clinical use (7). Still,
previous findings from the NOWAC Post-genome cohort
suggest that blood gene expression profiles differ between
future breast cancer cases and healthy controls up to 8 years
before diagnosis, stratifying on cancer stage and mode of
detection (8, 9). Routine mammography screening in Norway
is offered every two years to women over the age of 50.
Mammography-detected cancers are found at an earlier stage
of the carcinogenic process compared to clinically detected
cancers (10). Interval cancers, i.e., those that are detected in
the interval between screenings, are often of a more aggressive
type, as they arise and are clinically detected less than two years
after a screening mammogram (11).
In this study we used whole-genome gene expression data
from 197 breast cancer cases and age-matched controls from the
Norwegian Women and Cancer (NOWAC) Post-genome
cohort. Our aim was to investigate the potential differences
in blood gene expression profiles between patients with
metastasized cancer and patients with non-metastasized
cancer. This is an exploratory analysis to uncover promising
avenues for future research. Hence, we do not focus on
hypothesis testing and control of the error rates associated
with these procedures. Instead, we apply Bayesian modeling to
shrink estimates toward reasonable ranges.MATERIALS AND METHODS
The NOWAC study is a nationally representative, prospective
questionnaire-based cohort of approximately 170 000 middle-
aged women (12). Among NOWAC participants, approximately
50 000 women born in 1943-1957, were randomly selected and
invited to participate in the NOWAC Post-genome cohort (13).
During the years 2003-2006, these women provided blood samples
and additional questionnaires on lifestyle and reproductive factors
at the time of blood sampling. The blood samples were collected
using the PAXgene Blood RNA system (Preanalytix/Qiagen,
Hilden, Germany), which preserves the RNA profile of the
blood sample for future transcriptomic analysis.
The Cancer Registry of Norway provided information on
mammography screening attendance and clinical information on
cancer diagnoses. The most recent cancer registry update for theFrontiers in Oncology | www.frontiersin.org 2present study is from 2017. We defined breast cancer cases with a
positive lymph node status as metastatic cases. Breast cancer
subtypes were defined in accordance with the consensus (14) on
clinical and molecular classification of breast cancer tumors (15,
16). This is based on hormone receptor status (estrogen receptor:
ER, and progesterone receptor: PR) and human epidermal
growth factor receptor 2 (Her2). There was some missing
information on receptor and/or HER2 status: ER: 3 missing,
PR: 3 missing, and Her2: 19 missing. These cases were defined as
subtype unknown. Follow-up time was defined as the number of
days between the date of blood sample donation and the date
of diagnosis.
For our study, we started out with 231 women who were
diagnosed with breast cancer at most two years after providing a
blood sample. We drew age-matched, healthy controls from the
NOWAC Post-genome cohort. Due to missing data on height,
weight, or HRT use, we excluded seven cases and their
corresponding controls. We also excluded nine case/control
pairs due to missing information on screening attendance, and
three due to missing metastasis status. Finally, we excluded 15
case/control pairs due to missing gene expression data for the
control. This left a final study sample for data analysis of 197
breast cancer cases and 197 age-matched controls. Since we
compared cases with metastasis to cases without metastasis, the
controls served merely as a normalization of expression levels.
This is primarily useful to mitigate batch effects.
We performed all data processing and analysis in R, using the
Bioconductor and rstan packages (https://www.r-project.org/).
The code we produced for this project is available online at
https://github.com/uit-hdl/holsbo_olsen_2020.Laboratory Analyses and Data
Pre-Processing
The Illumina-certified Genomics Core Facility at the Norwegian
University of Science and Technology processed the blood
samples. We kept each case-control pair together throughout
the lab procedures to minimize technical variability, since the
pairs are always processed at the same time in the same batches.
Total RNA was isolated in accordance with the manufacturer’s
protocol (PAXgene Blood miRNA isolation Kit). RNA purity was
assessed by NanoDrop ND 8000 spectrophotometer
(ThermoFisher Scientific, Wilmington, DE, USA), and RNA
integrity by Bioanalyzer capillary electrophoresis (Agilent
Technologies, Palo Alto, CA, USA). mRNA was amplified and
labeled using the Illumina TotalPrepT-96 RNA Amplification
Kit (Ambion Inc., Austin, TX, USA), and hybridized to Illumina
HumanWG-6 v.3 Expression BeadChip microarrays (Illumina,
Inc. San Diego, CA, USA). The raw microarray images were
processed in Illumina GenomeStudio.
We performed preprocessing of the raw microarray data
according to the NOWAC standard procedure (17). Broadly
this comprises the following steps; see the code linked above and
the referenced manuscript for details:
1. Background correction of expression values using negative
control probes.October 2020 | Volume 10 | Article 575461
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3. Filter out genes expressed below detection threshold (p <
0.01).
4. Filter out rare genes expressed in fewer than 15% of our
observations.
5. Map Illumina probe IDs to gene symbols.
6. Remove probes with low annotation quality.
7. If several probes map to the same gene, keep the one with the
highest inter-quartile range in its measurements.
8. Define differential gene expression as the difference in log2
expression between a given case and its corresponding
control.
Finally, as a data reduction step, we removed 2012 genes
where the mean signal was more than 20 times the size of the
standard deviation, i.e., genes that show little variation. After
preprocessing, there were 6664 genes left in the gene
expression matrix.
Analysis Suggested by DAG
We investigated the relationship between immune system
activity, as measured by blood gene expression, and breast
cancer metastasis. To guide this investigation we mapped out a
causal diagram to the best of our ability. The diagram (Figure 1)
suggests that we can obtain a causal estimate by adjusting for
“aggression”. Since we cannot measure the aggressiveness
of a cancer directly, we used detection mode as a proxy
variable that could provide partial de-confounding. We hence
estimated separate sets of parameters for screening cancers and
interval cancers.Frontiers in Oncology | www.frontiersin.org 3Model
We modeled metastasis probability for a single gene g, pg, as a
function of differential expression, xg (i.e., log2 expressioncase –
log2 expressioncontrol). We did this by a Bayesian hierarchical
model, stratifying by mode of detection, s ∈{screening, interval}
with partial pooling between strata. For the observed metastatic
status of person i, yi ∈{0, 1}, we specified the following model:





= ag,si + bg,si xg,i, (2)
ag ,si ∼ normal −1, 1ð Þ, (3)
bg,si ∼ normal(mg,sg), (4)
mg ∼ normal 0, 0:1ð Þ, (5)
sg = e
s 0g , (6)
s 0g ∼ normal 0, 0:2ð Þ : (7)
The function logit(p) = log(p) − log(1 − p) is the logarithmic
odds of metastasis. Equations 1–4 describe a logistic regression
with varying slopes between detection methods. I.e. we
considered the association between risk and differential
expression to be similar but not identical for screening and
interval cancers. Equations 5–7 define the hyperpriors for theFIGURE 1 | Directed acyclic graph for the relationship between pre-diagnostic blood gene expression and breast cancer metastasis.October 2020 | Volume 10 | Article 575461
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used this non-centered parameterization because it makes the
estimation faster and more reliable. We estimated these models
using the NUTS sampler implemented in Stan (18). Having
estimated the posterior distributions for our parameters in each
detection setting, we integrated the detection setting out to








We standardized cg to have mean zero and standard deviation of
unity. This makes logit−1 (ag) the metastasis probability, or risk,
for an individual with average differential expression of gene g.
Likewise the quantity logit−1 (ag + zbg) is the risk for someone
with differential expression z standard deviations higher than the
average. We call the quantity
rg =  logit
−1(ag +  0:1bg) −  logit
−1(ag)
the excess risk of metastasis for gene g. We chose Z = 0.1
because in our data most differences in means between
metastases and non-metastases fall between ± 0.1 standard
deviations. Hence we considered this a reasonable increase in
differential expression for our investigation.
Excess risk is a signed quantity on the absolute scale. An excess
risk of 0.01, or 1%, means that the risk of someone with elevated
expression in a certain gene has a risk of 1% more than someone
with average expression. I.e. if the risk associated with average
expression is 25%, which it roughly tends to be, the risk of someone
with 2% excess risk is 27%. A negative excess risk suggests that
decreased expression has a higher metastatic risk, which implies
under-expression among metastatic cases. We use excess risk
throughout to assess how important the variation of a certain
gene’s expression is for metastatic spread.
Priors
We chose our priors to provide a slight shrinkage toward the null
effect. The prior parameters are chosen ad hoc to provide a
relaxed coverage of the parameter sizes we see fitting gene-wise
maximum likelihood regressions for other outcomes (smoking
and similar). This discourages outrageous estimates while still
lending credence to realistic sizes. Figure 2 shows priorFrontiers in Oncology | www.frontiersin.org 4predictive distributions for ags and bgs along with the implied
prior predictive distribution for excess risk. We have centered the
prior distribution for ags , the log odds for someone with average
expression, on what roughly corresponds to a risk of 25%, which
is what is seen in the population. The prior implied excess risk is
sharply peaked around 0 and has the middle 60% of its mass in
the range ± 0.014.
Ranking Genes and Gene Sets
The sign probability of an excess risk is p (rg > 0) when the
median of rg is positive and p(rg < 0) when the median is
negative. This probability lies between.5 and 1 and expresses how
much of the density for rg lies away from zero. A high sign
probability means that we are quite sure of the direction of an
excess risk but does not say anything about its magnitude. We
used sign probability both to rank genes and to rank gene sets.
We ranked genes in decreasing order by sign probability and
examined the first 100.
We ranked gene sets by the average sign probability in a given
set. We extracted gene sets from the Molecular Signatures
Database v.7.0 (MSigDB, (19)), using the following collections:
Hallmark gene sets (H, (20)), Curated gene sets (C2), and Gene
ontology gene sets-Biological processes (C5 BP). We examined
the top 50 sets among these collections.
Ethical Considerations
The NOWAC study was approved by the Norwegian Data
Inspectorate and the Regional Ethical Committee of North
Norway (reference: REK NORD 2010/2075). All women gave
written, informed consent. Collection and storage of biological
material was approved by the REK in accordance with the
Norwegian Biobank Act (reference: P REK NORD 141/2008
Biobanken Kvinner og Kreft ref. 200804332-3).RESULTS
In our study population of 394 middle-aged women (197 cases,
197 controls), age, BMI, smoking, and parity were similar
between breast cancer cases and controls (Table 1). HT use
among cases was slightly higher than among controls. Most
cancers diagnosed in the mammography screening program
were metastasis-free (82%, Table 2). This was much lower
among those diagnosed in the interval (53%). This difference
lends credibility to the decision to stratify by detection mode.
The Luminal A, Triple negative, and HER2 positive subtypesFIGURE 2 | Prior predictive distributions. Prior predictive distributions for ags and bgs along with the implied prior predictive distribution for excess risk of breast
cancer metastasis.October 2020 | Volume 10 | Article 575461
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However, for the latter two subtypes, the number of cases in each
group is very small, so it is difficult to draw conclusions
(Table 2).
Shrinkage Size
Figure 3 shows a comparison of excess risk estimates between
our posterior mean predictions and classical maximum
likelihood estimates. As expected, there is a slight shrinkage
toward an excess risk of null.
Genes and Gene Sets Associated With
Excess Risk of BC Metastasis
Figure 4 shows the estimated excess risk of metastasis for the 100
genes with the highest sign probability. The first part shows up-
regulated genes, and the second shows down-regulated genes.
We show the full list of 100 genes in Supplementary Table 1.
Out of these 100 genes, 42 were associated with increased riskFrontiers in Oncology | www.frontiersin.org 5(over-expressed in metastatic cases), and 58 were associated with
decreased risk (under-expressed in metastatic cases). Among the
genes associated with increased risk, some have been previously
described in plasmacytiod dentritic cells (pDCs), including
TARBP1, TNFRSF21, TPM2, DAB2, SCAMP5, and RIMS3.
There are also three genes related to glutamine metabolism
(SIRT4, PHGDH, CTPS1). Among the 58 single genes
associated with increased metastasis risk there are some related
to heme metabolism (e.g. BMP2K, RHC, RHD, SLC22A4,
SLC30A1), transmembrane transport of ammonium (e.g.
SLC22A4, -5, RHCE, RHD) and cations (those of ammonium
transport, as well as FKBP1A, SLC2A9, STEAP4). There are
several genes related to immunological processes (e.g. TRAF3,
LILRA5, SIGLEC9).
Table 3 and Supplementary Table 2 shows the top 20 and
top 50 gene sets associated with risk of metastasis, respectively.
The gene set results reflect the tendencies from the single gene
analysis, with processes including glutathione derivative
biosynthesis, ammonium transport, and immune functions
(macrophage activation, IL2 signaling, antigen processing)
being represented among the top 20 gene sets. In the gene set
G O _
GLUTATHIONE_DERIVATIVE_BIOSYNTHETIC_PROCESS
(Figure 5), the seven included genes were associated with both
increased risk (GSTM1, GSTM2) and decreased risk (MGST1).
In contrast, four members of the SLC22 family were associated
with decreased risk in the REACTOME_ORGANIC_
CATION_TRANSPORT gene set (Figure 6). To identify the
genes that drive the gene set results, we list genes present in
multiple gene sets in Table 4. Their association with metastasis
risk is displayed in Supplementary Figure 1. There were 18
genes present in three or more gene sets, four genes were present
in four gene sets (GSTM1, GSTM2, SLC22A16, SLC22A4), and
two genes were present in six gene sets (SLC22A5, SRC).DISCUSSION
In this study we analyzed gene expression profiles in
prospectively collected blood samples and examined genes and
gene sets associated with risk of BC metastasis. Among the top
genes, we identified pDC-related genes and processes like
glutamine metabolism, several SLC22 transporters, and





n 156 115 41
Age 56.1 56.1 56.2
BMI 25.5 25.6 26.2
Smoking 37 (24%) 26 (23%) 10 (24%)
HT use 29 (19%) 41 (36%) 12 (29%)
Parity 1.9 1.8 1.8BMI, body mass index; HT, hormone therapy.TABLE 2 | Characteristics of the breast cancer cases.
Non-metastasized Metastasized
Follow-up time 319 376
Detection mode
Screening 91 (79%) 20 (49%)
Interval 24 (21%) 21 (51%)
Subtypes
Luminal A 59 (51%) 26 (63%)
Luminal B 9 (8%) 4 (10%)
Triple negative 2 (2%) 3 (7%)
HER2 positive 0 3 (7%)
Unknown 45 (39%) 5 (12%)FIGURE 3 | Shrinkage of predictions. Posterior mean predictions from our Bayesian models, compared to classical maximum likelihood estimates (MLE) in terms of
predicted excess risk of breast cancer metastasis.October 2020 | Volume 10 | Article 575461
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excess risk lie mostly between 0 and.01, with some skew
toward higher excess risk. The trend is similar among the
down-regulated genes in the opposite direction. The sign
probability for the top 100 genes was generally high, with no
probability below 0.9. In the gene sets, average sign probability
lay in the range.75–.85.
Biological Aspects
Among the single genes associated with increased risk in our study,
some have been previously described in plasmacytoid dendritic cells
(pDCs) after vaccination against influenza (21). In general, pDCsFrontiers in Oncology | www.frontiersin.org 6are antigen presenting cells that initiate and coordinate immune
responses. In line with these functions, antigen processing and
presentation were among our top gene sets. pDCs have not been
extensively studied in the cancer setting (22). Nevertheless, their
presence in primary tumors were identified as negative prognostic
markers for overall and relapse-free survival of breast cancer (23). In
contrast, another study found positive association between
circulating pDCs and breast cancer survival (24). In the latter
study, there were lower levels of circulating pDCs in late stage
cancers, but metastatic cancers were not investigated. The six genes
related to pDCs were not found together in any of our investigated
gene sets. This may be due to the fact that pDCs are somewhatFIGURE 4 | ContinuedOctober 2020 | Volume 10 | Article 575461
FIGURE 4 | Genes associated with breast cancer risk. Distributions for excess risk of breast cancer metastasis for the up-regulated and down-regulated genes that
were present among the top 100 genes associated with risk. The middle area shaded with the deepest value is the region between the 0.45–0.55 quantile. Each
lightening of value extends these quantiles .05 in each direction (i.e. 0.4–0.6, 0.35– 0.65, etc.).
Holsbø and Olsen Metastasis and Blood Gene Expression
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MSigDB collections that we included for our gene set analysis.
Four members of the SLC22 family were among the genes most
frequently found in our gene set data, all of which were associated
with decreased risk of metastasis (i.e. down-regulated). Two were
among the top 100 single genes associated with metastasis risk. This
family of transporters are involved in diverse and ubiquitous
processes like metabolism, and inter-organ and inter-organism
signaling. A recent review suggests they have equal importance as
the neuroendocrine system and growth factor-cytokine system (25).
Their role in cation transport, carnitine handling, and drug/
xenobiotic metabolism can be recognized in our results.
However, as with all wide-ranging processes, specific hypotheses
for the role of the SLC22 family in immune processes related to
breast cancer metastasis cannot easily be reached based on
transcriptomic data.
We identified three single genes of glutamine metabolism
associated with increased risk of metastasis, and related gene sets
were among our top identified gene sets. Glutamine is the body’s
most abundant amino acid and is considered a “fuel for theFrontiers in Oncology | www.frontiersin.org 8immune system”. It is an essential amino acid for lymphocyte
proliferation, cytokine production, and activities of macrophages
and neutrophils (26). Low glutamine levels may impair immune
cell function, with detrimental health effects (26). Based on our
findings of differential expression of genes and gene sets related
to glutathione, one might speculate that activity in the immune
system is elevated in response to a metastatic tumor, as compared
to that of a non-metastatic tumor.
Methodological Aspects
DAGs are helpful for translating causal relationships into
associations and create an overview of the subject matter as a
basis for interdisciplinary discussions with the aim of designing an
analysis strategy. But as with any method, there are strengths and
weaknesses. Drawing the diagram to include all relevant
assumptions is a challenge, also because absence of an arrow is a
strong assumption. Nevertheless, drawing the DAG forces clarity
about the underlying assumptions. To the extent that the diagram
represents the true causal relationships, it helps identifying key
sources of bias.TABLE 3 | Top 20 gene sets associated with risk of BC metastasis, ranked by the average sign probability.




















GO_ENDODERMAL_CELL_FATE_COMMITMENT 0.767October 2020 | Volume 10 | AAvg. sign p., average sign probability.FIGURE 5 | Excess risk estimates for genes of the GO_GLUTATHIONE_DERIVATIVE_BIOSYNTHETIC_PROCESS gene set.rticle 575461
Holsbø and Olsen Metastasis and Blood Gene ExpressionFIGURE 6 | Excess risk estimates for genes of the REACTOME_ORGANIC_CATION_TRANSPORT gene set.TABLE 4 | Genes present in multiple gene sets.
gene n sets




SRC 6 GO_POSITIVE_REGULATION_OF_PODOSOME_ASSEMBLY, GO_TRANSCYTOSIS, PID_GLYPICAN_1PATHWAY,
PID_NFKAPPAB_ATYPICAL_PATHWAY, REACTOME_EPHRIN_SIGNALING,
REACTOME_P130CAS_LINKAGE_TO_MAPK_SIGNALING_FOR_INTEGRINS
GSTM1 4 GO_GLUTATHIONE_DERIVATIVE_BIOSYNTHETIC_PROCESS, GO_XENOBIOTIC_CATABOLIC_PROCESS,
KEGG_DRUG_METABOLISM_CYTOCHROME_P450,
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450
GSTM2 4 GO_GLUTATHIONE_DERIVATIVE_BIOSYNTHETIC_PROCESS, GO_XENOBIOTIC_CATABOLIC_PROCESS,
KEGG_DRUG_METABOLISM_CYTOCHROME_P450,
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450
SLC22A16 4 GO_AMMONIUM_TRANSMEMBRANE_TRANSPORT, GO_QUATERNARY_AMMONIUM_GROUP_TRANSPORT,
REACTOME_ORGANIC_CATION_ANION_ZWITTERION_TRANSPORT,
REACTOME_ORGANIC_CATION_TRANSPORT
SLC22A4 4 GO_AMMONIUM_TRANSMEMBRANE_TRANSPORT, GO_QUATERNARY_AMMONIUM_GROUP_TRANSPORT,
REACTOME_ORGANIC_CATION_ANION_ZWITTERION_TRANSPORT,
REACTOME_ORGANIC_CATION_TRANSPORT









GSTO2 3 GO_GLUTATHIONE_DERIVATIVE_BIOSYNTHETIC_PROCESS, KEGG_DRUG_METABOLISM_CYTOCHROME_P450,
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450
GSTT1 3 GO_GLUTATHIONE_DERIVATIVE_BIOSYNTHETIC_PROCESS, KEGG_DRUG_METABOLISM_CYTOCHROME_P450,
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450
GSTZ1 3 GO_GLUTATHIONE_DERIVATIVE_BIOSYNTHETIC_PROCESS, KEGG_DRUG_METABOLISM_CYTOCHROME_P450,
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450
KIT 3 GO_EPITHELIAL_CELL_CELL_ADHESION, GO_PHASIC_SMOOTH_MUSCLE_CONTRACTION,
MATZUK_SPERMATOGONIA
LCK 3 PID_GLYPICAN_1PATHWAY, PID_NFKAPPAB_ATYPICAL_PATHWAY, REACTOME_INTERLEUKIN_2_SIGNALING
LTC4S 3 GO_LIPOXYGENASE_PATHWAY, REACTOME_SYNTHESIS_OF_LEUKOTRIENES_LT_AND_EOXINS_EX,
RUAN_RESPONSE_TO_TNF_TROGLITAZONE_UP
MGST1 3 GO_GLUTATHIONE_DERIVATIVE_BIOSYNTHETIC_PROCESS, KEGG_DRUG_METABOLISM_CYTOCHROME_P450,
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450
SLC25A20 3 GO_AMMONIUM_TRANSMEMBRANE_TRANSPORT, GO_QUATERNARY_AMMONIUM_GROUP_TRANSPORT,
REACTOME_IMPORT_OF_PALMITOYL_COA_INTO_THE_MITOCHONDRIAL_MATRIXFrontiers in Oncology | www.frontiersin.orgn, number of gene sets.October 2020 | Volume 10 | Article 5754619
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cancer. In the broad context, these risk factors act through two
main mechanisms: either through DNA damage, or through
hormone-related processes. Age, alcohol use, and smoking
(Figure 1, blue) all increase cancer risk by causing accumulation
of DNA damage in the cells. On the other hand, exposure to
endogenous hormones (Figure 1, yellow) implies the exposure of
cells to mitogenic substances. Higher hormone exposure levels
(early onset of menarche, few or no pregnancies, use of HT), in
combination with presence of non-maturated cells (late or
no pregnancies, lack of breastfeeding) increases the risk of
uncontrolled cell division in those cells. Responsiveness to
hormone levels in both normal and cancerous cells depend on the
presence of receptors like ER and PR. A few risk factors act through
a combination of genetic and hormonal mechanisms (Figure 1,
green). For example, in postmenopausal women, the fatty tissue
produces estrogen (27); and excess body fat causes systemic
inflammation and intracellular stress, which may increase DNA
damage (28).
Strengths and Limitations
Our data is from a case-control study nested within the
prospective NOWAC Post-genome cohort. The advantage of
this study design is that recall bias is reduced because exposure
information is collected prospectively, before the onset of disease.
Also, selection bias is reduced due to the prospective cohort
being population-based. However, the nested case-control study
cannot be used to infer causality between the exposure and the
outcome. Specifically, it is not possible to measure and
statistically control for all variables that may affect breast
cancer metastasis. Hence the observed associations may
be confounded.
The blood samples from all participants were taken before
diagnosis of the disease. All the same, the cancer and/or the
metastasis may already be present, but clinically undetected. We
cannot determine if the gene expression profile is a cause or a
consequence of the cancer and/or metastasis. This limitation also
relates to the structure of the DAG: we have defined the gene
expression profile, as a proxy for immune system activity, to be
causally related to the metastasis. But this may not be biologically
accurate. There is a very close and complex interaction between the
immune system and the metastatic cancer that acts both via direct
cell-cell contact and via excreted factors. Extracellular and intracellular
signaling pathways are often redundant, two-way, and containing
feedback loops. None of thesemechanisms can be easily expressed via
a DAG. One solution might be to map out the molecular two-way
interactions and feedback loops as linear sequences of events in time
(29), but this is beyond the scope of our work.
Although it is possible for us to build this DAG on the macro-
scale of epidemiology, it is nigh impossible to do so on themolecular
level. We have made no effort to do so and simply do gene-by-gene
regressions. Hence there is almost certainly confounding on the
molecular level, as genes are known to operate together in pathways.
Along with the causality-related limitations discussed above,
which pertain to our study design and time of blood sampling,Frontiers in Oncology | www.frontiersin.org 10we stress that gene expression profiling is in its nature hypothesis
generating. In line with this, we have chosen a statistical
approach that focusses on model-based exploration as opposed
to the testing of hypotheses. In building our statistical model we
have made an effort to be scrupulous in reporting our
assumptions. We made some of these choices for convenience,
such as the use of single-gene regressions and the use of hard-
coded prior parameters rather than a hierarchical model. We
have explored other approaches to these data not reported here,
notably (8, 30).CONCLUSION
In this work we have explored associations between breast cancer
metastasis and prospective blood gene expression profiles. We
conducted a Bayesian data analysis guided by a causal DAG to
identify genes and pathways associated with risk of metastasis.
Our results point to pDC function, the ubiquitous SLC22 family
of transporters, and glutamine metabolism as candidates for
future studies of the link between the immune system
and metastasis.
We have identified potentially wide-reaching differences
between metastatic and non-metastatic cases. The identified
processes reflect both recently discovered links between the
immune system and breast cancer metastasis, in the case of
pDCs, and more well-described pathways, like regulation of the
immune system by glutamine. Although the excess risk estimates
are small in magnitude, our findings provide potentially
important clues to the interaction between the immune system
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